A randomized controlled trial of antipsychotic combination in acute-phase schizophrenia - A randomized controlled trial of antipsychotic combination in schizophrenia

Seventy-eight patients completed 2 weeks of treatment, and divided into early responders to risperidone (n=52), and early non-responders to risperidone (the RIS+OLZ group, n=13; the RIS+RIS group, n=13). At 10 weeks, there was no significant difference in the achievement of >=50% response between the two early non-responder groups (23% vs. 23%). Remarkably, difference in time to treatment discontinuation for any cause between early responders to risperidone and the RIS+OLZ group was not found (8.6 weeks [95%CI: 7.9-9.3] vs. 7.9 weeks [6.3-9.5], P=0.37) although that was significantly longer in early responders to risperidone than in the RIS+RIS group (8.6 weeks [7.9-9.3] vs. 6.8 weeks [5.2-8.4], P=0.018).